Endo's Paladin Labs Reports Canadian Introduction Of Veregen

Paladin Labs Inc., a subsidiary of Endo International plc ENDP ENL and a leading Canadian specialty pharmaceutical company, today announced the launch of Veregen® (sinecatechins) Ointment, 10%, a topical treatment for external genital and perianal warts (condylomata acuminata) in immunocompetent patients aged 18 years and over. Clinically visible warts are present in approximately 1% of sexually active adults, making genital warts the most common sexually transmitted infection(1). Studies have demonstrated that for individuals with external genital warts, the reduction in their quality of life is of similar magnitude to that seen in people with moderate to severe asthma or osteoarthritis(2). "We are pleased to announce the launch of Veregen® in Canada," said Mark Beaudet, President of Paladin Labs Inc. "Sexually transmitted infections (STIs) such as external genital warts can cause tremendous psychological stress(3). Canadians who suffer from external genital warts now have a new, non-invasive and effective topical treatment option with a demonstrated tolerability profile." Paladin obtained the exclusive rights to market Veregen® in Canada from Medigene AG in May 2014. About Veregen: Veregen® (sinecatechins) Ointment 10% is a topical treatment for external genital and perianal warts (condylomata acuminata) in immunocompetent patients aged 18 years and over. It is available in a 15g tube. The drug substance in Veregen® is sinecatechins, which is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis (L.) O Kuntze and is a mixture of catechins and other green tea components. The most common side effects with Veregen® Ointment are local skin and application site reactions, but these should decrease over time(4). Sinecatechins 10% & 15% Ointment (Veregen®) has been included in the 2012 European Guideline for the Management of Anogenital Warts. In addition, in its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% Ointment (Veregen®) as a possible option for treating genital warts.